

KEYPAD Trial News

www.anzup.org.au

KEYPAD Recruitment Update – November 2021

16 TO GO

Thanks for your feedback on the restrictive 14 days window between consent and registration. We recently extended this window to 28 days to facilitate the screening process at site. Please keep KEYPAD on the agenda at your MDT meetings, share emails/newsletters with your colleagues to encourage cross-referral and follow any leads for potential patients.

Thank you for your ongoing efforts and commitment to reach end of recruitment. With only 16 participants to go we are eager to receive any eligibility or protocol questions and welcome any feedback to KEYPAD.study@sydney.edu.au.

Site accrual

SITE NAME	PARTICIPANTS TO DATE
Calvary Mater Newcastle	11
Concord Repatriation General Hospital	8
St George Hospital	8
Sunshine Coast University Hospital	5
Royal Brisbane & Women's Hospital	4
Fiona Stanley Hospital	4
Flinders Medical Centre	3
Monash Health	2
Ballarat Oncology and Haematology Services	2
Townsville Hospital	2
Icon Cancer Care	1
GenesisCare (formerly Northern Cancer Institute)	1
Eastern Health / Box Hill	1
Border Medical Oncology	1
Peter MacCallum Cancer Center (closed)	1
St Vincent's Hospital (Sydney)	0
Total	54/70

What is KEYPAD?

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial.

STUDY CHAIR

**A/Professor
Craig Gedye**



Thoughts from a Trial Investigator – Michelle Morris

Dr Michelle Morris is a medical oncologist at the Sunshine Coast University Hospital. Dr Morris worked as a medical oncologist for Cancer Research UK, Leeds, before returning to Australia in 2005 consultant position at Nambour General Hospital. Since then, she has consulted at Nambour General Hospital, Gympie Hospital and in private practice on the Sunshine Coast. Dr Morris has experience treating a broad range of solid tumour malignancies, with areas of interest including breast cancer, gastrointestinal and urological malignancies. She has been active in improving cancer clinical trial access on the Sunshine Coast and promoting quality, multidisciplinary care for her patients.



Her first exposure to clinical trials was when training to become an oncologist in Brisbane. During her fellowship year in Leeds in the UK, her main role was to be responsible for the day to day running of their clinical trials in renal cancer and melanoma. This provided great experience. It was an exciting time with new oral therapies just starting to be trialed in this group of patients - and this definitely helped develop her interest in clinical trial work. Michelle has now been the site principal investigator on almost 50 clinical trials since commencing work on the Sunshine Coast in 2005. She is proud to have been the lead in building the clinical trial capacity within the regional service and advocating over the years for the importance of clinical trials as part of the core service to their patients. They have expanded from having only conducted a few oncology trials with one trial coordinator, to now consistently having up to 10 trials recruiting at any one time and 5 trial coordinators.

Being a trial investigator does have its challenges. One such challenge is having time within busy clinics for the additional assessments and documentation which are so important in clinical trials. But working towards consistent systems for all trials is crucial. Although trial systems and approvals are improving, the different processes and systems for each trial can be confusing and time consuming to navigate. However, making trials work better and more efficiently can happen. Dr Morris believes it is important to choose trials which make you feel excited to be part of. If you and your colleagues are passionate about the new drug or intervention and the possible benefits for your patients, the trial is more likely to be successful at your site.

FRIENDLY REMINDER

Please refer to the COVID-19 Guidance Document for information to assist with managing your KEYPAD participants and protocol trial assessments. Please record and forward any deviations using the provided COVID Deviation Log and contact the CTC with any questions or issues.

KEYPAD is a collaboration between ANZUP and NHMRC Clinical Trials Centre.



This investigator initiated ANZUP study has been supported both financially and with study drug by MSD and Amgen.



MSD

AMGEN[®]
Oncology

ANZUP is supported by the Australian Government through Cancer Australia.



Australian Government
Cancer Australia

KEYPAD key contacts

- Clinical trial operations, CTC E: keypad.study@sydney.edu.au
- Coordinating PI: Craig Gedye E: craig.gedye@newcastle.edu.au
- Sponsor queries (payments, contracts) E: trials@anzup.org.au
- More info on KEYPAD: <https://anzup.org.au/clinical-trial/keypad/>